Evofem Biosciences, Inc.

Evofem Biosciences, Inc. is a U.S.-based pharmaceutical company focused on commercializing women’s health products. Its core business centers on PHEXXI for pregnancy prevention and SOLOSEC for bacterial vaginosis and trichomoniasis, supported by telehealth and third-party commercialization channels.

16,8 %

77,1 %

1,9 %

+4,2 %

0.18

0.17

— Evofem Biosciences, Inc.
%
Women’s health pharmaceuticals85% Prescription products used for pregnancy prevention and treatment of women’s health infections.
Telehealth-enabled access10% Digital and remote channels used to support patient access and prescribing for PHEXXI.
Commercialization and promotion5% Sales, marketing, and distribution activities supporting approved products.

Evofem sells primarily into the prescription healthcare market, where the end users are patients and the economic...

  • Women seeking contraceptionprimary

    Patients and prescribers using PHEXXI for pregnancy prevention, often valuing a non-hormonal option.

  • Women treated for BV and trichomoniasisprimary

    Patients prescribed SOLOSEC for bacterial vaginosis and trichomoniasis treatment.

  • Physicians and telehealth prescribersprimary

    Clinicians who write prescriptions and determine whether the products are adopted in practice.

  • Pharmacies and distributorssecondary

    Channel partners that stock, dispense, and distribute the products to end users.

  • Payers and reimbursement gatekeeperssecondary

    Insurers and benefit managers that affect patient affordability and product uptake.

The company is headquartered in the United States and the available disclosures point to a primarily U.S...

  • •Headquartered in the United States
  • •Commercial activity appears concentrated in the U.S. prescription market
  • •U.S. FDA regulation is central to product labeling and promotion
  • •Telehealth strategy depends on state-level rules and reimbursement
  • •Supply chain and third-party manufacturing risk are global, not local

Evofem’s strategy is to keep PHEXXI and SOLOSEC commercially viable through direct marketing, telehealth access, and...

01
Commercialize PHEXXI more effectivelyshort-term

PHEXXI is a core growth driver and depends on physician and patient acceptance.

02
Sustain SOLOSEC sales and market accessshort-term

SOLOSEC provides an additional approved product and diversifies the women’s health portfolio.

03
Reduce dependence on third partiesmedium-term

Manufacturing, distribution, and telehealth are outsourced and create execution risk.

Evofem is highly exposed to commercialization risk because its revenue depends on whether PHEXXI and SOLOSEC gain and...

high

Commercial acceptance of PHEXXI

Revenue depends heavily on whether physicians and patients adopt the product over competing contraceptive options.

Scope
Core product revenue
Materiality
high
high

Dependence on third-party manufacturing and distribution

The company relies on two contract manufacturers and has limited internal distribution capability.

Scope
Supply continuity and product availability
Materiality
high
high

FDA and promotion compliance

Prescription products are subject to strict rules on labeling and off-label promotion.

Scope
Commercialization and legal risk
Materiality
high
medium

Telehealth execution risk

The PHEXXI telehealth platform depends on third parties, provider participation, and favorable state rules.

Scope
Patient access channel
Materiality
medium
medium

Product liability and post-marketing claims

Approved healthcare products can still face lawsuits, adverse events, or market setbacks after launch.

Scope
Litigation and reputation
Materiality
medium
Variable consideration reserves
Can materially change reported net sales and gross-to-net deductions
Fair value of financial instruments
Can create volatility in other income/expense and reported earnings
Revenue recognition and trade receivables
Affects timing of revenue and allowance/reserve levels
Contingencies and indemnifications
May affect liabilities and cash flow if claims are triggered

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Zivo Bioscience, Inc.

ZIVO · Biological Products, (No Diagnostic Substances)

VivoSim Labs, INC.

VIVS · Biological Products, (No Diagnostic Substances)

Evolus, Inc.

EOLS · Pharmaceutical Preparations

Zeo ScientifiX, Inc.

ZEOX · Biological Products, (No Diagnostic Substances)

EXOZYMES INC.

EXOZ · Biological Products, (No Diagnostic Substances)

: 28.4.2026